Nitrate tolerance: A unifying hypothesis

Circulation

Volumn 106, Issue 19, 2002, Pages 2510-2513

  Gori, Tommaso ^a   Parker, John D ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Acethlcholine; Blood flow; Endothelium; Nitric oxide synthase; Nitroglycerin

Indexed keywords

NITRATE;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG TOLERANCE; DRUG TRANSFORMATION; HUMAN; HYPOTHESIS; LONG TERM CARE; META ANALYSIS; PLASMA VOLUME; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; BIOTRANSFORMATION; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; HUMANS; NITRATES; NITRIC OXIDE SYNTHASE; PEROXYNITROUS ACID; PLASMA VOLUME; SIGNAL TRANSDUCTION; SUPEROXIDES;

EID: 0037027487     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000036743.07406.53     Document Type: Short Survey

References (59)

1. Munzel T, Kurz S, Heitzer T, et al. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol. 1996;77:24C-30C.
2. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520-531.
3. Packer M. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol. 1990;16:932-935.
4. Armstrong PW, Moffat JA. Tolerance to organic nitrates: Clinical and experimental perspectives. Am J Med. 1983;74:73-84.
5. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation. 1991; 84:2336-2345.
6. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990;16:923-931.
7. Parker JD. Counterregulatory responses: Sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol. 1996;28:631-638.
8. Jurt U, Gori T, Ravandi A, et al. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: A human in vivo study. J Am Coll Cardiol. 2001;38:854-859.
9. Romero JC, Reckelhoff JF. Oxidative stress may explain how hypertension is maintained by normal levels of angiotensin II. Braz J Med Biol Res. 2000;33:653-660.
10. Zhao X, Alexander JS, Zhang S, et al. Redox regulation of endothelial barrier integrity. Am J Physiol Lung Cell Mol Physiol. 2001;281:L879-L886.
11. Parker JD, Farrell B, Fenton T, et al. Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol. 1992;20:616-622.
12. Parker JD, Parker AB, Farrell B, et al. Effects of diuretics therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Circulation. 1996;93:691-696.
13. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709-715.
14. Laursen JB, Mulsch A, Boesgaard S, et al. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation. 1996;94:2241-2247.
15. Fung HL, Poliszczuk R. Nitrosothiol and nitrate tolerance. Z Kardiol. 1986;75(suppl 3):25-27.
16. Sage PR, de LL, Stafford I, et al. Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation. 2000;102:2810-2815.
17. Miller MR, Megson IL, Roseberry MJ, et al. Novel s-nitrosothiols do not engender vascular tolerance and remain effective in glyceryl trinitrate-tolerant rat femoral arteries. Eur J Pharmacol. 2000;403:111-119.
18. Sutsch G, Kim JH, Bracht C, et al. Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance. Clin Pharmacol Ther 1997;62:538-545.
19. Gori T, Mak SS, Kelly S, et al. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol. 2001;38:1096-1101.
20. Bohyn M, Berkenboom G, Fontaine J. Effect of nitrate tolerance and dipyridamole on the response to SIN1 in the human isolated saphenous vein. Cardiovosc Drugs Ther. 1991;5:457-461.
21. Mulsch A, Mordvintcev P, Bassenge E, et al. In vivo spin trapping of glyceryl trinitrate-derived nitric oxide in rabbit blood vessels and organs. Circulation. 1995;92:1876-1882.
22. Bredt DS, Hwang PM, Glatt CE, et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991;351:714-718.
23. McDonald BJ, Bennett BM. Cytochrome P450 mediated biotransformation of organic nitrates. Can J Physiol Pharmacol. 1990;68:1552-1557.
24. Ratz JD, McGuire JJ, Anderson DJ, et al. Effects of the flavoprotein inhibitor, diphenyleneiodonium sulfate, on ex vivo organic nitrate tolerance in the rat. J Pharmacol Exp Ther. 2000;293:569-577.
25. Minamiyama Y, Imaoka S, Takemura S, et al. Escape from tolerance of organic nitrate by induction of cytochrome P450. Free Radic Biol Med. 2001;31:1498-1508.
26. Kojda G, Patzner M, Hacker A, et al. Nitric oxide inhibits vascular bioactivation of glyceryl trinitrate: A novel mechanism to explain preferential venodilation of organic nitrates. Mol Pharmacol. 1998;53:547-554.
27. Needleman P, Jakschik B, Johnson EM Jr. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther. 1973;187:324-331.
28. Boesgaard S, Aldershvile J, Poulsen HE, et al. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res. 1994;74:115-120.
29. Hofmann H, Schmidt HH. Thiol dependence of nitric oxide synthase. Biochemistry. 1995;34:13443-13452.
30. Seth P, Fung HL. Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol. 1993;46:1481-1486.
31. Daiber A, Herold S, Schoneich C, et al. Nitration and inactivation of cytochrome P450BM-3 by peroxynitrite, stopped-flow measurements prove ferryl intermediates. Eur J Biochem. 2000;267:6729-6739.
32. Mehl M, Daiber A, Herold S, et al. Peroxynitrite reaction with heme proteins. Nitric Oxide. 1999;3:142-152.
33. Wong PS, Eiserich JP, Reddy S, et al. Inactivation of glutathione s-transferases by nitric oxide-derived oxidants: Exploring a role for tyrosine nitration. Arch Biochem Biophys. 2001;394:216-228.
34. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99:8306-8311.
35. Brown GC. Nitric oxide and mitochondrial respiration. Biochim Biophys Acta. 1999;1411:351-369.
36. Molina CR, Andresen JW, Rapoport RM, et al. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol. 1987;10:371-378.
37. Kowaluk EA, Fung HL. Dissociation of nitrovasodilator-induced relaxation from cyclic GMP levels during in vitro nitrate tolerance. Eur J Pharmacol. 1990;176:91-95.
38. Soff GA, Cornwell TL, Cundiff DL, et al. Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest. 1997;100:2580-2587.
39. Ratz JD, McGuire JJ, Anderson DJ, et al. Effects of the flavoprotein inhibitor, diphenyleneiodonium sulfate, on ex vivo organic nitrate tolerance in the rat. J Pharmacol Exp Ther. 2000;293:569-577.
40. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
41. Axelsson KL, Ahlner J. Nitrate tolerance from a biochemical point of view. Drugs. 1987;33(suppl 4):63-68.
42. Kim D, Rybalkin SD, Pi X, et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 2001;104:2338-2343.
43. Mulsch A, Oelze M, Kloss S, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation. 2001;103:2188-2194.
44. Weber M, Lauer N, Mulsch A, et al. The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med. 2001;31:1360-1367.
45. Guthrie F. Contributions to the knowledge of the amyl group. J Chem Soc. 1859;11:245-252.
46. Kamisaki Y, Waldman SA, Murad F. The involvement of catalytic site thiol groups in the activation of soluble guanylate cyclase by sodium nitroprusside. Arch Biochem Biophys. 1986;251:709-714.
47. Artz JD, Schmidt B, McCracken JL, et al. Effects of nitroglycerin on soluble guanylate cyclase: Implications for nitrate tolerance. J Biol Chem. 2002;277: 18253-18256.
48. Khan SA, Higdon NR, Meisheri KD. Coronary vasorelaxation by nitroglycerin: Involvement of plasmalemmal calcium-activated K+ channels and intracellular Ca++ stores. J Pharmacol Exp Ther. 1998;284:838-846.
49. Liu Y, Gutterman DD. Oxidative stress and potassium channel function. Clin Exp Pharmacol Physiol. 2002;29:305-311.
50. Grover AK, Samson SE. Effect of superoxide radical on Ca2+ pumps of coronary artery. Am J Physiol. 1988;255(pt 1):C297-C303.
51. Fink B, Dikalov S, Bassenge E. A new approach for extracellular spin trapping of nitroglycerin-induced superoxide radicals both in vitro and in vivo. Free Radic Biol Med. 2000;28:121-128.
52. Dikalov S, Fink B, Skatchkov M, et al. Formation of reactive oxygen species in various vascular cells during glyceryltrinitrate metabolism. J Cardiovasc Pharmacol Ther. 1998;3:51-62.
53. Gruhn N, Boesgaard S, Eiberg J, et al. Effects of large conductance Ca(2+)-activated K(+) channels on nitroglycerin-mediated vasorelaxation in humans. Eur J Pharmacol. 2002;446:145-150.
54. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343:1115-1122.
55. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-685.
56. Death AK, Nakhla S, McGrath KC, et al. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol. 2002;39:1943-1950.
57. Nakamura Y, Moss AJ, Brown MW, et al. Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138(pt 1):577-585.
58. Zanzinger J, Czachurski J, Seller H. Impaired modulation of sympathetic excitability by nitric oxide after long-term administration of organic nitrates in pigs. Circulation. 1998;97:2352-2358.
59. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry. 1998;37:1613-1622.